Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 184

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis

Open access
Borie, Raphael, Tabèze, Laure, Thabut, Gabriel, Nunes, Hilario, Cottin, Vincent, Marchand-Adam, Sylvain, Prevot, Grégoire, Tazi, Abdellatif, Cadranel, Jacques, Mal, Herve, Wemeau-Stervinou, Lidwine, Bergeron Lafaurie, Anne, Israel-Biet, Dominique, Picard, Clement, Reynaud Gaubert, Martine, Jouneau, Stephane, Naccache, Jean-Marc, Mankikian, Julie, Ménard, Christelle, Cordier, Jean-François, Valeyre, Dominique, Reocreux, Marion, Grandchamp, Bernard, Revy, Patrick, Kannengiesser, Caroline, Crestani, Bruno · 2016 · European Respiratory Journal

Abstract

Telomerase reverse transcriptase ( TERT ) or telomerase RNA ( TERC ) gene mutation is a major monogenic cause of pulmonary fibrosis. Sequencing of TERT / TERC genes is proposed to patients with familial pulmonary fibrosis. Little is known about the possible predictors of this mutation and its impact on prognosis. We retrospectively analysed all the genetic diagnoses made between 2007–2014 in patients with pulmonary fibrosis. We evaluated the prevalence of TERT / TERC disease-associated variant (DAV), factors associated with a DAV, and the impact of the DAV on survival. 237 patients with pulmonary fibrosis (153 with familial pulmonary fibrosis, 84 with telomere syndrome features without familial pulmonary fibrosis) were tested for TERT / TERC DAV. DAV was diagnosed in 40 patients (16.8%), including five with non-idiopathic interstitial pneumonia. Prevalence of TERT / TERC DAV did not significantly differ between patients with familial pulmonary fibrosis or with only telomere syndrome features (18.2% versus 16.4%). Young age, red blood cell macrocytosis, and low platelet count were associated with the presence of DAV; the probability of DAV was increased for patients 40–60 years. Transplant-free survival was lower with than without TERT / TERC DAV (4.2 versus 7.2 years; p=0.046). TERT / TERC DAV were associated with specific clinical and biological features and reduced transplant-free survival.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/13993003.02115-2015

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 184

Metadata

Authors
Borie, R., Tabèze, L., Thabut, G., Nunes, H., Cottin, V., Marchand-Adam, S., Prevot, G., Tazi, A., Cadranel, J., Mal, H., Wemeau-Stervinou, L., Bergeron Lafaurie, A., Israel-Biet, D., Picard, C., Reynaud Gaubert, M., Jouneau, S., Naccache, J.-M., Mankikian, J., Ménard, C., Cordier, J.-F., Valeyre, D., Reocreux, M., Grandchamp, B., Revy, P., Kannengiesser, C., & Crestani, B.
Venue
European Respiratory Journal
Published
2016-11-11
Volume
48
Issue
6
Pages
1721-1731
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W2554008299
Cited by
184
References
10
FWCI
13.77
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis. https://app.cochat.ai/papers/10.1183/13993003.02115-2015
The paper
Borie, R., Tabèze, L., Thabut, G., Nunes, H., Cottin, V., Marchand-Adam, S., Prevot, G., Tazi, A., Cadranel, J., Mal, H., Wemeau-Stervinou, L., Bergeron Lafaurie, A., Israel-Biet, D., Picard, C., Reynaud Gaubert, M., Jouneau, S., Naccache, J.-M., Mankikian, J., Ménard, C., . . . Crestani, B. (2016). Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis. European Respiratory Journal. https://doi.org/10.1183/13993003.02115-2015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.